Suppr超能文献

V-Go(®)一次性胰岛素给药装置与多次皮下注射胰岛素在基础胰岛素治疗血糖控制不佳的2型糖尿病患者中的临床疗效及成本效益比较

CLINICAL AND COST-EFFECTIVENESS OF INSULIN DELIVERY WITH V-GO(®) DISPOSABLE INSULIN DELIVERY DEVICE VERSUS MULTIPLE DAILY INJECTIONS IN PATIENTS WITH TYPE 2 DIABETES INADEQUATELY CONTROLLED ON BASAL INSULIN.

作者信息

Lajara Rosemarie, Davidson Jaime A, Nikkel Carla C, Morris Tracy L

出版信息

Endocr Pract. 2016 Jun;22(6):726-35. doi: 10.4158/EP151182.OR. Epub 2016 Feb 1.

Abstract

OBJECTIVE

To compare two methods of delivering intensified insulin therapy (IIT) in patients with type 2 diabetes inadequately controlled on basal insulin ± concomitant antihyperglycemic agents in a real-world clinical setting.

METHODS

Data for this retrospective study were obtained using electronic medical records from a large multicenter diabetes system. Records were queried to identify patients transitioned to V-Go(®) disposable insulin delivery device (V-Go) or multiple daily injections (MDI) using an insulin pen to add prandial insulin when A1C was >7% on basal insulin therapy. The primary endpoint was the difference in A1C change using follow-up A1C results.

RESULTS

A total of 116 patients were evaluated (56 V-Go, 60 MDI). Both groups experienced significant glycemic improvement from similar mean baselines. By 27 weeks, A1C least squares mean change from baseline was -1.98% (-21.6 mmol/mol) with V-Go and -1.34% (-14.6 mmol/mol) with MDI, for a treatment difference of -0.64% (-7.0 mmol/mol; P = .020). Patients using V-Go administered less mean ± SD insulin compared to patients using MDI, 56 ± 17 units/day versus 78 ± 40 units/day (P<.001), respectively. Diabetes-related direct pharmacy costs were lower with V-Go, and the cost inferential from baseline per 1% reduction in A1C was significantly less with V-Go ($118.84 ± $158.55 per patient/month compared to $217.16 ± $251.66 per patient/month with MDI; P = .013).

CONCLUSION

Progression to IIT resulted in significant glycemic improvement. Insulin delivery with V-Go was associated with a greater reduction in A1C, required less insulin, and proved more cost-effective than administering IIT with MDI.

ABBREVIATIONS

A1C = glycated hemoglobin ANCOVA = analysis of covariance CI = confidence interval CSII = continuous subcutaneous insulin infusion FPG = fasting plasma glucose IIT = intensified insulin therapy LSM = least squares mean MDI = multiple daily injections T2DM = type 2 diabetes mellitus TDD = total daily dose.

摘要

目的

在真实临床环境中比较两种强化胰岛素治疗(IIT)方法,用于基础胰岛素±联合降糖药物治疗血糖控制不佳的2型糖尿病患者。

方法

本回顾性研究的数据来自一个大型多中心糖尿病系统的电子病历。查询记录以识别在基础胰岛素治疗时糖化血红蛋白(A1C)>7%,转而使用V-Go(®)一次性胰岛素输注装置(V-Go)或胰岛素笔多次皮下注射(MDI)追加餐时胰岛素的患者。主要终点是根据随访A1C结果得出的A1C变化差异。

结果

共评估了116例患者(56例使用V-Go,60例使用MDI)。两组均从相似的平均基线水平实现了显著的血糖改善。到27周时,使用V-Go的患者A1C自基线的最小二乘均值变化为-1.98%(-21.6 mmol/mol),使用MDI的患者为-1.34%(-14.6 mmol/mol),治疗差异为-0.64%(-7.0 mmol/mol;P = 0.020)。与使用MDI的患者相比,使用V-Go的患者平均胰岛素剂量更低(标准差),分别为56±17单位/天和78±40单位/天(P<0.001)。V-Go的糖尿病相关直接药房费用更低,且每降低1% A1C的基线成本推断显著低于MDI(每位患者每月118.84±158.55美元,而MDI为每位患者每月217.16±251.66美元;P = 0.013)。

结论

进展至IIT可显著改善血糖。与使用MDI进行IIT相比,使用V-Go输注胰岛素可使A1C降低幅度更大,所需胰岛素更少,且更具成本效益。

缩写

A1C = 糖化血红蛋白;ANCOVA = 协方差分析;CI = 置信区间;CSII = 持续皮下胰岛素输注;FPG = 空腹血糖;IIT = 强化胰岛素治疗;LSM = 最小二乘均值;MDI = 多次皮下注射;T2DM = 2型糖尿病;TDD = 每日总剂量

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验